Latest:
IP Attorneys Propose a New Biosimilar Pathway in Case of ACA Repeal
© 2023 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest:
Opinion: Purple Book Patent Listings Are Only a First Step
Latest:
Julie Reed On How the Biosimilars Forum is Helping FDA Catch Up on Biosimilar Inspections
Latest:
Contributor: Interchangeability Is a Dispensing Issue, Not a Prescribing One
Latest:
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?
Latest:
Contributor: The Biosimilars Wave Is Crashing on the Shores of Biopharma Development